Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency

Modern Pathology

Volumn 27, Issue 10, 2014, Pages 1405-1411

  Reyes, M Carolina ^a   Arnold, Angela G ^a   Kauff, Noah D ^a,b   Levine, Douglas A ^a,b   Soslow, Robert A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

BRCA; Metastasis; Ovarian carcinoma; Serous carcinoma; Transitional cell carcinoma

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; CANCER MORPHOLOGY; CANCER PATIENT; FEMALE; GENE MUTATION; GENOTYPE; GERMLINE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; SOMATIC MUTATION; TUMOR INVASION; UTERINE TUBE CARCINOMA; CANCER GRADING; CYSTADENOCARCINOMA; GENETICS; OVARY TUMOR; PATHOLOGY; TUMOR SUPPRESSOR GENE; UTERINE TUBE TUMOR;

CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS;

EID: 84930337120     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.237     Document Type: Article

References (18)

1. Tisserand P, Fouquet C, Barrois M, et al. Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors. Cancer Biol Ther 2003;2:559-563.
2. Armes JE, Egan AJM, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998;83:2335-2345.
3. Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000;6:782-789.
4. Wong EM, Southey MC, Fox SB, et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res 2011;4:23-33.
5. Soslow RA, Han G, Park KJ, et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 2012;25:625-636.
6. Fujiwara M, McGuire VA, Felberg A, et al. Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype. Am J Surg Pathol 2012;36:1170-1177.
7. Kommoss F, Kommoss S, Schmidt D, et al. Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. Gynecol Oncol 2005;97:195-199.
8. Verhaak RG, Tamayo P, Yang JY, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2013;123:517-525.
9. Karamurzin Y, Leitao MM Jr., Soslow RA. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal. Am J Surg Pathol 2013;37:356-367.
10. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol l 2008;39:1239-1251.
11. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. l 2008;27:161-174.
12. Ali RH, Seidman JD, Luk M, et al. Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor. Int J Gynecol Pathol 2012;31:499-506.
13. Takeuchi T, Ohishi Y, Imamura H, et al. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma. Am J Surg Pathol 2013;37:1091-1099.
14. Garg K, Levine DA, Olvera N, et al. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J Surg Pathol 2013;37:138-146.
15. Hyman DM, Long KC, Tanner EJ, et al. Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecol Oncol 2012;126:224-228.
16. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115:1234-1244.
17. Winter WE 3rd, Maxwell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2008;26:83-89.
18. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-1259.